JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB177619

重组人 Apolipo蛋白 CI/Apo-CI (His tag N-Terminus)

Recombinant Human Apolipoprotein CI/Apo-CI (His tag N-Terminus)

Be the first to review this product! Submit a review

|

(1 Publication)

Recombinant Human Apolipoprotein CI/Apo-CI (His tag N-Terminus) is a Human Full Length protein, in the 27 to 83 aa range, expressed in Escherichia coli, with >90%, suitable for SDS-PAGE, Mass Spec.

查看别名

Apolipoprotein C-I, Apo-CI, ApoC-I, Apolipoprotein C1, APOC1

1 Images
SDS-PAGE - Recombinant Human Apolipoprotein CI/Apo-CI (His tag N-Terminus) (AB177619)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Human Apolipoprotein CI/Apo-CI (His tag N-Terminus) (AB177619)

3ug by SDS-PAGE under reducing condition and visualized by coomassie blue stain.

关键信息

纯度

>90% SDS-PAGE

表达系统

Escherichia coli

标签

His tag N-Terminus

应用

SDS-PAGE, Mass Spec

applications

生物活性

No

访问

P02654

不含动物源

No

不含载体蛋白

No

种属

Human

存储溶液

pH: 8 Constituents: 10% Glycerol (glycerin, glycerine), 0.88% Sodium chloride, 0.32% Tris HCl

storage-buffer

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "Mass Spec": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

产品详情

This product was previously labelled as Apolipoprotein CI

序列信息

[{"sequence":"MGSSHHHHHHSSGLVPRGSHMGSTPDVSSALDKLKEFGNTLEDKARELISRIKQSELSAKMREWFSETFQKVKEKLKIDS","proteinLength":"Full Length","predictedMolecularWeight":"9 kDa","actualMolecularWeight":null,"aminoAcidEnd":83,"aminoAcidStart":27,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":"P02654","tags":[{"tag":"His","terminus":"N-Terminus"}]}]

性能和储存信息

运输条件
Blue Ice
推荐的短期储存时间
1-2 weeks
推荐的短期储存条件
+4°C
推荐的长期储存条件
-20°C
分装信息
Upon delivery aliquot
储存信息
Avoid freeze / thaw cycle
False

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

Apolipoprotein CI (Apo-CI) plays a mechanical role in lipid metabolism where it acts as an inhibitor of lipoprotein lipase and hepatic lipase hindering lipolytic activity. It is also known as 'apo 250' and 'apo atv20' with a molecular mass of approximately 6.6 kDa. Apo-CI is primarily expressed in the liver and secreted into the plasma where it associates with high-density lipoproteins (HDL) and very low-density lipoproteins (VLDL).
Biological function summary

Apo-CI influences plasma triglyceride levels and cholesterol homeostasis. It plays a role in lipid transport and metabolism by modulating the binding of other apolipoproteins such as apo A-IV and interfering with the binding of lipoproteins to their receptors. Apo-CI is part of a complex of apolipoproteins that regulate lipid metabolism working in tandem to balance lipid and cholesterol levels in the body.

Pathways

Apo-CI is actively involved in the lipoprotein metabolism pathway and cholesterol efflux pathway. These pathways are important in maintaining lipid balance and cardiovascular health. Apo-CI is related to other apolipoproteins within these pathways such as apo E and apo A-I. Its function in modulating lipoprotein receptor interactions aligns with the broader mechanisms of these pathways in lipid and cholesterol regulation.

Elevated levels of Apo-CI are associated with hyperlipidemia and cardiovascular disease. These conditions may result from its inhibitory effects on lipase activity leading to increased triglyceride levels. Apo-CI's interaction with other apolipoproteins such as apo B and apo E is linked to its role in the pathogenesis of these disorders. Understanding Apo-CI's involvement in these diseases can guide therapeutic strategies aimed at regulating its expression and function.

特殊说明

形式

Liquid

附加说明

ab177619 is purified by using conventional chromatography techniques.

常规信息

功能

Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.

序列相似性

Belongs to the apolipoprotein C1 family.

产品实验方案

靶点信息

Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.
See full target information APOC1

文献 (1)

Recent publications for all applications. Explore the full list and refine your search

iScience 24:103538 PubMed34917906

2021

CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism.

Applications

Unspecified application

Species

Unspecified reactive species

Jean-Philippe Guégan,Justine Pollet,Christophe Ginestier,Emmanuelle Charafe-Jauffret,Marcus E Peter,Patrick Legembre
View all publications

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂,为您科研的每一步提供支持。若我们的产品未能达到预期性能,我们向您提供 Abcam Product Promise 保障。
详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com